Released on: February 4, 2008, 9:52 am

Press Release Author: McGill Reporter

Industry: Education

Press Release Summary: Since the 2004 inception of the THES annual rankings, McGill
has always fared well-the only Canadian university to have made the top 25 every
year. While the school\'s ranking has consistently improved (from 24th in 2005 to
21st in 2006), the nine-place jump this year is significant, especially following
the recent launch of Campaign McGill.

Press Release Body: Times Higher Ed rankings

In the just-released annual Times Higher-QS World University Rankings, McGill
University placed 12th overall-the first time a Canadian university has cracked the
top 15 to join Harvard, Oxford, Cambridge, Yale and others among the dozen best
universities in the world. The school also ranked ahead of such prestigious US
universities as Duke, Stanford, John Hopkins and Cornell. As with last year, Harvard
topped the list, with Oxford, Cambridge and Yale tied for second. McGill also had
the distinction of being classed as the best public university on the continent. The
University of British Columbia (33rd) and the University of Toronto (45th) were the
only other two Canadian universities to crack the Top 50.

Since the 2004 inception of the THES annual rankings, McGill has always fared
well-the only Canadian university to have made the top 25 every year. While the
school\'s ranking has consistently improved (from 24th in 2005 to 21st in 2006), the
nine-place jump this year is significant, especially following the recent launch of
Campaign McGill.

\"This news is particularly gratifying coming from the Times Higher-QS, which is
respected the world over,\" said McGill Principal and Vice-Chancellor Heather
Munroe-Blum. \"At a time when universities are generating knowledge and talent for a
global marketplace and for a society seeking solutions to increasingly complex
problems through research and innovation, this recognition of McGill\'s role as a
world leader is a tribute to the exceptional quality and commitment of our students,
faculty and staff.\"


\"This news is particularly gratifying coming from the Times Higher-QS, which is
respected the world over,\"

Heather Munroe-Blum
McGill Principal and Vice-Chancellor



About McGill University Health Centre:
The McGill University Health Centre (MUHC), located in Montreal, Quebec, is one of
the most comprehensive university health centers in North America. The MUHC
represents five teaching hospitals affiliated with the Faculty of Medicine of McGill
University: The Montreal Children\'s, Montreal General, Royal Victoria, and Montreal
Neurological hospitals, as well as the Montreal Chest Institute. The Research
Institute of the MUHC is an internationally recognized biomedical and healthcare
hospital research centre. The Institute supports over 500 researchers as well as
1,000 graduate and postdoctoral students. It operates more than 300 laboratories
devoted to a broad spectrum of fundamental and clinical research and it produces
over 1,400 publications per year.

About Samaritan Therapeutics, Montreal, Canada:
Samaritan Therapeutics, Inc. is a Canadian company based in Montreal, Canada, that
performs its scientific research and development in Canada. Samaritan Therapeutics
has a research and development collaboration with The Research Institute of McGill
University Health Center to develop new and improved innovative drugs to relieve the
suffering of patients with Alzheimer\'s, Cancer, Heart disease, and Infectious
disease.

Samaritan Pharmaceuticals: ``Transforming Today\'s Science Into Tomorrow\'s Cures...\'\'
Samaritan Pharmaceuticals is a life science company focused on commercializing
innovative drugs to relieve the suffering of patients with Alzheimer's, Cancer,
Heart disease, and Infectious disease.

Website: http://www.samaritanpharma.com. Please register so we can notify you of
upcoming conference calls, news and events.

Disclaimer:
The company disclaims any information that is created by an outside party and
endorses only information that is communicated by its press releases, filings, and
Website. This news release contains forward-looking statements that reflect
management\'s current beliefs about the potential for its drug candidates, science,
and technology. However, as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development and regulatory
review. There are no guarantees that products will prove to be commercially
successful. For additional information about the factors that affect the company\'s
business, please read the company\'s latest Form 10-K filed April 13, 2007. The
company undertakes no duty to update forward-looking statements.

Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210

Samaritan Pharmaceuticals, Inc.
Kristi Eads
702-735-7001


Web Site:
http://www.samaritanpharma.com/news_11-16-07_International_Ranking_of_Universities_McGill_Cracks_Distinguished_Dozen.asp


Contact Details: Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210

Samaritan Pharmaceuticals, Inc.
101 Convention Center Drive, Suite 310
Las Vegas, NV 89081
Kristi Eads
702-735-7001